129 related articles for article (PubMed ID: 35718065)
21. β-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/ mTOR signalling pathways.
Zhan YH; Liu J; Qu XJ; Hou KZ; Wang KF; Liu YP; Wu B
Asian Pac J Cancer Prev; 2012; 13(6):2739-44. PubMed ID: 22938451
[TBL] [Abstract][Full Text] [Related]
22. Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells.
Zeng Y; Tian X; Wang Q; He W; Fan J; Gou X
Drug Des Devel Ther; 2018; 12():911-920. PubMed ID: 29719377
[TBL] [Abstract][Full Text] [Related]
23. Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma.
Reddy GK; Mughal TI; Rini BI
Clin Genitourin Cancer; 2006 Sep; 5(2):110-3. PubMed ID: 17026798
[TBL] [Abstract][Full Text] [Related]
24. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
25. The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
Zou Y; Wang J; Leng X; Huang J; Xue W; Zhang J; Huang Y
Oncotarget; 2017 Mar; 8(13):20825-20833. PubMed ID: 28212559
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
27. Telmisartan-Induced Cytotoxicity via G
Tsujiya Y; Hasegawa A; Yamamori M; Okamura N
Biol Pharm Bull; 2021; 44(12):1878-1885. PubMed ID: 34853271
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
Cho DC; Cohen MB; Panka DJ; Collins M; Ghebremichael M; Atkins MB; Signoretti S; Mier JW
Clin Cancer Res; 2010 Jul; 16(14):3628-38. PubMed ID: 20606035
[TBL] [Abstract][Full Text] [Related]
29. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway.
Liu H; Li X; Duan Y; Xie JB; Piao XL
J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477
[TBL] [Abstract][Full Text] [Related]
31. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
Yuen JS; Akkaya E; Wang Y; Takiguchi M; Peak S; Sullivan M; Protheroe AS; Macaulay VM
Mol Cancer Ther; 2009 Jun; 8(6):1448-59. PubMed ID: 19509240
[TBL] [Abstract][Full Text] [Related]
32. Bisebromoamide, an extract from Lyngbya species, induces apoptosis through ERK and mTOR inhibitions in renal cancer cells.
Suzuki K; Mizuno R; Suenaga K; Teruya T; Tanaka N; Kosaka T; Oya M
Cancer Med; 2013 Feb; 2(1):32-9. PubMed ID: 24133625
[TBL] [Abstract][Full Text] [Related]
33. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
Shang D; Han T; Xu X; Liu Y
Int J Clin Exp Pathol; 2015; 8(9):11140-8. PubMed ID: 26617834
[TBL] [Abstract][Full Text] [Related]
34. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
35. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis and therapeutic options.
Brown RE; Buryanek J; Tammisetti VS; McGuire MF; Csencsits-Smith K
Oncotarget; 2016 Jul; 7(27):41612-41621. PubMed ID: 27223432
[TBL] [Abstract][Full Text] [Related]
36. Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells.
Fujiwara D; Tsubaki M; Takeda T; Tomonari Y; Koumoto YI; Sakaguchi K; Nishida S
Tumour Biol; 2017 Oct; 39(10):1010428317734947. PubMed ID: 28990465
[TBL] [Abstract][Full Text] [Related]
37. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
38. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.
Lin A; Piao HL; Zhuang L; Sarbassov dos D; Ma L; Gan B
Cancer Res; 2014 Mar; 74(6):1682-93. PubMed ID: 24448243
[TBL] [Abstract][Full Text] [Related]
39. Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies.
Santoni M; Molina-Cerrillo J; Myint ZW; Massari F; Buchler T; Buti S; Matrana MR; De Giorgi U; Rizzo M; Zabalza IO; Galli L; Zucali PA; Aurilio G; Incorvaia L; Bassanelli M; Mammone G; Salfi A; Isella L; Mollica V; Grande E; Porta C; Battelli N
Target Oncol; 2022 Sep; 17(5):571-581. PubMed ID: 35947324
[TBL] [Abstract][Full Text] [Related]
40. Dauricine inhibits viability and induces cell cycle arrest and apoptosis via inhibiting the PI3K/Akt signaling pathway in renal cell carcinoma cells.
Zhang S; Ren Y; Qiu J
Mol Med Rep; 2018 May; 17(5):7403-7408. PubMed ID: 29568902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
